Search research articles
Contact Us
Filters
Showing results (81-90 of 208) with videos related to
Page
of 21
Sort By:
International Journal of Molecular Sciences
|
February 24, 2024
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, et al.
Journal of Translational Medicine
|
April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020
Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Nature Communications
|
March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes
Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Clinical Genitourinary Cancer
|
April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Kathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
Katherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Melanoma Management
|
August 22, 2020
Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
James Sun, Brian R Gastman, Lucy McCahon, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
Jason A Chesney, Igor Puzanov, Frances A Collichio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Page
of 21
Search research articles
Search
Showing results (81-90 of 208) with videos related to
Sort By:
Page
of 21
International Journal of Molecular Sciences
|
February 24, 2024
Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises
Wen Jess Li, Yunfei Wang, Xiaozhuo Liu, et al.
Journal of Translational Medicine
|
April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020
Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.
Nature Communications
|
March 4, 2021
T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors
Takayoshi Yamauchi, Toshifumi Hoki, Takaaki Oba, et al.
Biorxiv : the Preprint Server for Biology
|
July 17, 2025
Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes
Anmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 21, 2020
Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
Jean-François Martini, Elizabeth R Plimack, Toni K Choueiri, et al.
Clinical Genitourinary Cancer
|
April 3, 2016
Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma
Kathleen M Mahoney, Susanna Jacobus, Rupal S Bhatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2013
BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition
Katherine E Hutchinson, Doron Lipson, Philip J Stephens, et al.
Melanoma Management
|
August 22, 2020
Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2)
James Sun, Brian R Gastman, Lucy McCahon, et al.
Journal for Immunotherapy of Cancer
|
May 4, 2023
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
Jason A Chesney, Igor Puzanov, Frances A Collichio, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2021
Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
Page
of 21